​

NeuroSense Therapeutics Stock (NASDAQ:NRSN)

OwnershipFinancialsChart

Previous Close

$1.28

52W Range

$0.51 - $2.33

50D Avg

$1.12

200D Avg

$1.16

Market Cap

$29.83M

Avg Vol (3M)

$241.85K

Beta

1.56

Div Yield

-

NRSN Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

18

IPO Date

Dec 09, 2021

Website

NRSN Performance

NRSN Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-13.30M$-13.55M$-5.59M
Net Income$-11.28M$-11.20M$-2.50M
EBITDA$-13.21M$-13.38M$-8.28M
Basic EPS$-0.83$-0.97$-1.29
Diluted EPS$-0.83$-0.97$-1.29

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
KPRXKiora Pharmaceuticals, Inc.
LGVNLongeveron Inc.
REVBRevelation Biosciences, Inc.
BDRXBiodexa Pharmaceuticals Plc
NTRBNutriband Inc.
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
RNXTRenovoRx, Inc.
NRBONeuroBo Pharmaceuticals, Inc.